%0 Generic
%A Neukam, Karin
%A Espinosa, Nuria
%A Merino, Dolores
%A Rivero-Juárez, Antonio
%A Carrero, Ana
%A Ríos, María José
%A Ruiz-Morales, Josefa
%A Gómez-Berrocal, Ana
%A Téllez, Francisco
%A Díaz-Menéndez, Marta
%A Collado, Antonio
%A Pérez-Camacho, Inés
%A Delgado-Fernández, Marcial
%A Vera-Méndez, Francisco
%A Pineda, Juan A.
%T Hepatic safety of RPV/FTC/TDF single tablet regimen in HIV/HCV-coinfected patients. Preliminary results of the hEPAtic Study
%D 2014
%U http://hdl.handle.net/10668/2533
%X Although hepatotoxicity related to antiretroviral treatment (ART) has become less frequent, hepatotoxic events,such as transaminase elevations (TE), are still a matter of concern. RPV/FTC/TDF (EPA) is a new single tablet regimen which iswidely used in real life practice. Clinical trials showed an adequate profile of liver safety in the sub-population of HIV/HCV-coinfected patients receiving rilpivirine. However, the number of individuals included in these analyses is low [1]. The aim of thisongoing study is to evaluate the incidence of TE and total bilirubin elevations (TBE) during the first 48 weeks of EPA-basedtherapy in a large population of HIV/HCV-coinfected subjects outside of clinical trials.
%K Bilirrubina
%K Protocolos clínicos
%K Coinfección
%K Hepatitis C
%K Combinación emtricitabina, rilpivirina y tenofovir
%~